Subsequent Event	3 Months Ended
Mar. 31, 2019
Subsequent Events [Abstract]
Subsequent Event	12. Subsequent Event On April 8, 2019, the Company entered into a co-promotion agreement (the Glenmark Co-Promotion Agreement) with Glenmark Therapeutics Inc., USA (Glenmark), pursuant to which Glenmark will exclusively promote OTIPRIO for AOE in the United States to ear, nose and throat (ENT) physician offices. Glenmark will make non-refundable, non-creditable payments to the Company during each year of the Glenmark Co-Promotion Agreement and Glenmark will reimburse the Company for a proportion of product support expenses as agreed upon by both parties. Glenmark has agreed to bear the costs incurred for its promotion of OTIPRIO. In exchange for its promotional services, Glenmark is entitled to receive a share of gross profits totaling more than 50% from the sale of OTIPRIO to Glenmark’s accounts. The Company’s payments to Glenmark for its portion of the gross profits will be recognized as selling, general and administrative expenses in the Company’s condensed statements of operations. The Company retains all commercial rights for other customer segments for AOE and for use of OTIPRIO in other indications. The initial term of the Glenmark Co-Promotion Agreement is five years with provisions for extension and early termination.

Subsequent Event

3 Months Ended

Mar. 31, 2019

12. Subsequent Event

On April 8, 2019, the Company entered into a co-promotion agreement (the Glenmark Co-Promotion Agreement) with Glenmark Therapeutics Inc., USA (Glenmark), pursuant to which Glenmark will exclusively promote OTIPRIO for AOE in the United States to ear, nose and throat (ENT) physician offices. Glenmark will make non-refundable, non-creditable payments to the Company during each year of the Glenmark Co-Promotion Agreement and Glenmark will reimburse the Company for a proportion of product support expenses as agreed upon by both parties. Glenmark has agreed to bear the costs incurred for its promotion of OTIPRIO. In exchange for its promotional services, Glenmark is entitled to receive a share of gross profits totaling more than 50% from the sale of OTIPRIO to Glenmark’s accounts. The Company’s payments to Glenmark for its portion of the gross profits will be recognized as selling, general and administrative expenses in the Company’s condensed statements of operations. The Company retains all commercial rights for other customer segments for AOE and for use of OTIPRIO in other indications. The initial term of the Glenmark Co-Promotion Agreement is five years with provisions for extension and early termination.